FDA Approves Inclisiran as First-Line LDL-C Treatment Without Statins
The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with statins, according to Novartis. The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies. “This first-line label update reinforces Leqvio’s proven ability to effectively lower LDL-C, a critical risk factor […]